Lakeshore Biopharma (LSB) Stock Price, News & Analysis

Company Overview

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

Key Stats

• Today's Range: $2.43 to $2.79
• 50-Day Range: $2.00 to $8.37
• 52-Week Range: $1.88 to $11.20
• Volume: 4,165 shs
• Average Volume: 20,359 shs
• Market Capitalization: $22.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Lakeshore Biopharma Stock Analysis - MarketRank™

Lakeshore Biopharma scored higher than 12% of companies evaluated by MarketBeat, and ranked 932nd out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Lakeshore Biopharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Lakeshore Biopharma has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.42% of the float of Lakeshore Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Lakeshore Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lakeshore Biopharma has recently increased by 75.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lakeshore Biopharma does not currently pay a dividend.

Dividend Growth

Lakeshore Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.42% of the float of Lakeshore Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Lakeshore Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lakeshore Biopharma has recently increased by 75.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.43

News Sentiment

Lakeshore Biopharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Lakeshore Biopharma this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Lakeshore Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lakeshore Biopharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

52.64% of the stock of Lakeshore Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LSB Stock Analysis - Frequently Asked Questions

How have LSB shares performed this year?

Lakeshore Biopharma's stock was trading at $4.7030 at the start of the year. Since then, LSB stock has decreased by 48.3% and is now trading at $2.43.
View the best growth stocks for 2024 here.

When did Lakeshore Biopharma's stock split?

Lakeshore Biopharma's stock reverse split before market open on Friday, October 4th 2024. The 1-10 reverse split was announced on Friday, September 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Lakeshore Biopharma's major shareholders?

Top institutional shareholders of Lakeshore Biopharma include FMR LLC (12.51%), Hhlr Advisors LTD. (8.08%) and Barclays PLC (2.66%).

How do I buy shares of Lakeshore Biopharma?

Shares of LSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Lakeshore Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lakeshore Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC).

Company Calendar

• Today: 11/18/2024
• Next Earnings (Estimated): 1/27/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LSB
• Previous Symbol: NASDAQ:LSB
• CUSIP: N/A
• CIK: 1946399
• Web: N/A
• Phone: 17327133678
• Fax: N/A
• Employees: 773
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 1.13
• Quick Ratio: 0.87

Sales & Book Value

• Annual Sales: $80.82 million
• Price / Sales: 0.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.86 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 9,310,000
• Free Float: N/A
• Market Cap: $22.62 million
• Optionable: N/A
• Beta: 0.72